MG Matt Gline Biotech industry voice who hosts Off-Target Effects with Matt Gline, a BiotechTV interview series with investors and company leaders such as Perceptive's Joe Ed...

“I have a sneaking suspicion that the upfront components of these deals are secretly getting larger over time. It used to be people were trying to publish biobucks so as to conceal a low upfront in an overall big number. It may be that now the opposite is happening: biobucks numbers are being used by the buyer to keep quieter about the size of the upfront, to buy flexibility on their next deals.”

Biotech Hangout · Health & Longevity · November 2026

“I have a sneaking suspicion that the upfront components of these deals are secretly getting larger over time. It used to be people were trying to publish biobucks so as to conceal a low upfront in an overall big number. It may be that now the opposite is happening: biobucks numbers are being used by the buyer to keep quieter about the size of the upfront, to buy flexibility on their next deals.” — Matt Gline, Biotech Hangout

Context

The hosts were complaining that headline "up to $X billion" licensing deals are too opaque to show real value. Gline offers a contrarian reading of why buyers now keep the upfront payment quiet.

Transcript

Biotech Hangout Around 33:19 into the episode
Graig Suvannavejh

…I think there's more opacity around when we hear these deals done. What exactly is the value that's being played? And that's true, whether it's a licensing deal or an acquisition with earnouts. You still really don't know what is going to be exchanged. So, just briefly opening that up, any comments

Tim Opler

on have you guys seen kind of an increase in the marketing of these BioBuck deals? Anyone?

Matt Gline

Can I say, I, for what it's worth, this is a tradition as old as the sun in biotech and goes back since long before I was in the industry. And I guess, like, my view, if I had to guess, is that if anything, that it used to be that people would do $10 million upfront, billion and a half dollar milestone kind of deals and call them up to a billion and a half dollars. And I'm sure that still happens. But I have a sneaking suspicion that the upfront components of these deals is secretly getting larger over time. And that if anything, that what used to be happening is that people were trying to publish BioBucks deals so as to conceal the fact that they had received a low upfront in an overall big number. And that it may be the case now that actually the opposite is happening: that BioBucks numbers and up to numbers are being used, in fact, by the buyer to keep quieter about the size of the upfront in a transaction to buy them flexibility on their next deals. Like, I can think of a BioBucks announced deal by Eli Lilly a little while ago that I had interest in, where I did some underground digging, and it seemed like potentially the upfront was very large in a way that I suspect the…

Graig Suvannavejh

Yeah, I think that's right, Matt. And again, I'm not suggesting these are low upfronts. I think it's just interesting. I, you know, whoever wants to conceal it, right? But Lilly, I mean, just to put in perspective, 30 plus billion in acquisition. That's almost a rounding error for their market cap…

Tim Opler

like their strategy of really doing a big land grab. And I mean, I don't know how they're going to manage all of it. Integrate all of this to manage that many programs. I mean, obviously, they can hire people, but hiring quality people and keeping on top of it all, I'm sure they're employing AI to…

Graig Suvannavejh

conversation in our industry has reached a fever pitch recently with the Anthropic IPO and with the isomorphic labs. But Bruce Booth posted something that got a lot of following and engagement on X, basically talking about China versus AI and almost like we have these two massive behemoths, and he…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.

More from Biotech Hangout